Ozempic and GLP‑1 drugs hit insurance limits, side‑effect worries

GLP‑1 medicines such as Ozempic, Wegovy and Zepbound improve blood‑sugar control and promote weight loss, and clinical reviews rate them cost‑effective. However, insurers in the United States continue to restrict reimbursement, and analysts warn that widespread adoption could add billions to health‑plan budgets, exceeding ICER’s budget‑impact threshold.

Patients report side‑effects beyond gastrointestinal issues, including a low‑frequency increase in hair loss documented in a recent BMJ analysis. Health authorities in Europe note rising reimbursements for semaglutide – from about 322,000 courses in 2020 to over 4 million in 2024 in Italy – while also warning about counterfeit online sales that can cause serious harm.

Medical guidance emphasizes that Ozempic requires a prescription and should be used under professional supervision. Diet adjustments are important for those on GLP‑1 agents. Insurance‑savings cards and programs exist, but affordability remains a challenge for many, especially without coverage.